glp 1 hashimoto's disease Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study Microdosing GLP-1 for Hashimoto's: Evidence,
Description
They are side effects that typically improve as the body adjusts to the medication
Its time to get the support you need
Differences in cancer outcome definitions across trials were addressed by grouping clinically equivalent endpoints (e.g., hepatocellular carcinoma and primary liver cancer) and accounting for heterogeneity through random-effects modeling, sensitivity analyses, and GRADE downgrading for indirectness where appropriate
doi: 10.1038/nrcardio.2011.211
